Discovery, biosynthesis, and engineering of lantipeptides

Annual Review of Biochemistry

Volumn 81, Issue , 2012, Pages 479-505

  Knerr, Patrick J ^a   Van Der Donk, Wilfred A ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

genome mining; lantibiotic; leader peptide; posttranslational modification; ribosomally synthesized natural product

Indexed keywords

ANTIINFECTIVE AGENT; HYDROLYASE; LANTHIONINE; LANTIBIOTIC; LANTIPEPTIDE; METHYLLANTHIONINE; NATURAL PRODUCT; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; BACTERIAL GENOME; BIOINFORMATICS; CROSS LINKING; ENZYME ACTIVITY; ESCHERICHIA COLI; GRAM POSITIVE BACTERIUM; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STABILITY; PROTEIN STRUCTURE; REVIEW;

BACTERIA; BACTERIOCINS; BIOLOGICAL AGENTS; GENETIC ENGINEERING; PEPTIDES; PROTEIN PROCESSING, POST-TRANSLATIONAL;

BACTERIA (MICROORGANISMS); POSIBACTERIA;

EID: 84861649020     PISSN: 00664154     EISSN: 15454509     Source Type: Book Series    
DOI: 10.1146/annurev-biochem-060110-113521     Document Type: Review

References (164)

1. Veĺasquez JE, Van der Donk WA. 2011. Genome mining for ribosomally synthesized natural products. Curr. Opin. Chem. Biol. 15:11-21
2. OmanTJ, Van der Donk WA. 2010. Follow the leader: the use of leader peptides to guide natural product biosynthesis. Nat. Chem. Biol. 6:9-18
3. McIntosh JA, DoniaMS, Schmidt EW. 2009. Ribosomal peptide natural products: bridging the ribosomal and nonribosomal worlds. Nat. Prod. Rep. 26:537-59
4. Nolan EM, Walsh CT. 2009. How nature morphs peptide scaffolds into antibiotics. ChemBioChem 10:34-53
5. Chatterjee C, Paul M, Xie L, Van der DonkWA. 2005. Biosynthesis and mode of action of lantibiotics. Chem. Rev. 105:633-84
6. Willey JM, Van der Donk WA. 2007. Lantibiotics: peptides of diverse structure and function. Annu. Rev. Microbiol. 61:477-501
7. Bierbaum G, SahlHG.2009. Lantibiotics:mode of action, biosynthesis and bioengineering. Curr. Pharm. Biotechnol. 10:2-18
8. Piper C, Cotter PD, Ross PR, Hill C. 2009. Discovery of medically significant lantibiotics. Curr. Drug Discov. Technol. 6:1-18
9. Cotter PD, Hill C, Ross RP. 2005. Bacteriocins: developing innate immunity for food. Nat. Rev. Microbiol. 3:777-88
10. Smith L, Hillman JD. 2008. Therapeutic potential of type A (I) lantibiotics, a group of cationic peptide antibiotics. Curr. Opin. Microbiol. 11:401-8
11. Asaduzzaman SM, Sonomoto K. 2009. Lantibiotics: diverse activities and unique modes of action. J. Biosci. Bioeng. 107:475-87
12. Breukink E, de Kruijff B. 2006. Lipid II as a target for antibiotics. Nat. Rev. Drug Discov. 5:321-23
13. Cooper LE, Li B, Van der Donk WA. 2009. Biosynthesis and mode of action of lantibiotics. In Comprehensive Natural Products II: Chemistry and Biology, ed. L Mander, H-w Liu, 5:217-56. Oxford: Elsevier
14. Draper LA, Ross RP, Hill C, Cotter PD. 2008. Lantibiotic immunity. Curr. Protein Pept. Sci. 9:39-49
15. Goto Y, Li B, Claesen J, Shi Y, Bibb MJ, Van der Donk WA. 2010. Discovery of unique lanthionine synthetases reveals new mechanistic and evolutionary insights. PLoS Biol. 8:e1000339
16. Lubelski J, Rink R, Khusainov R, Moll G, Kuipers O. 2008. Biosynthesis, immunity, regulation, mode of action and engineering of the model lantibiotic nisin. Cell. Mol. Life Sci. 65:455-76
17. Grasemann H, Stehling F, Brunar H, Widmann R, Laliberte TW, et al. 2007. Inhalation of Moli1901 in patients with cystic fibrosis. Chest 131:1461-66
18. Sedgwick T, Dawson MJ. 2009. Novacta targets C. difficile the natural way. MedNous May 6:8-9
19. Donadio S, Maffioli S, Monciardini P, Sosio M, Jab́es D. 2010. Antibiotic discovery in the twenty-first century: current trends and future perspectives. J. Antibiot. 63:423-30
20. Ghobrial O, DerendorfH, Hillman JD. 2010. Pharmacokinetic and pharmacodynamic evaluation of the lantibiotic MU1140. J. Pharm. Sci. 99:2521-28
21. Zhao M, Li Z, Bugenhagen S. 2008. 99mTc-labeled duramycin as a novel phosphatidylethanolaminebinding molecular probe. J. Nucl. Med. 49:1345-52
22. Hasper HE, Kramer NE, Smith JL, Hillman JD, Zachariah C, et al. 2006. An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II. Science 313:636-37
23. Hsu S-TD, Breukink E, Tischenko E, Lutters MAG, de Kruijff B, et al. 2004. The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. Nat. Struct. Mol. Biol. 11:963-67
24. Hasper HE, de Kruijff B, Breukink E. 2004. Assembly and stability of nisin-lipid II pores. Biochemistry 43:11567-75
25. B̈ ottigerT, Schneider T, Martinez B, SahlHG, Wiedemann I. 2009. Influence of Ca2+ ions on the activity of lantibiotics containing a mersacidin-like lipid II binding motif. Appl. Environ. Microbiol. 75:4427-34
26. Hsu S-TD, Breukink E, Bierbaum G, Sahl HG, de Kruijff B, et al. 2003. NMR study of mersacidin and lipid II interaction in dodecylphosphocholinemicelles: Conformational changes are a key to antimicrobial activity. J. Biol. Chem. 278:13110-17
27. Dufour A, Hindŕe T, Haras D, Le Pennec J-P. 2007. The biology of lantibiotics from the lacticin 481 group is coming of age. FEMS Microbiol. Rev. 31:134-67
28. Hsu S-TD, Breukink E, Kaptein R. 2006. Structural motifs of lipid II-binding lantibiotics as a blueprint for novel antibiotics. Anti-Infect. Agents Med. Chem. 5:245-54
29. Wiedemann I, B̈ ottiger T, Bonelli RR, Wiese A, Hagge SO, et al. 2006. The mode of action of the lantibiotic lacticin 3147-a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II. Mol. Microbiol. 61:285-96
30. Oman TJ, Van der Donk WA. 2009. Insights into the mode of action of the two-peptide lantibiotic haloduracin. ACS Chem. Biol. 4:865-74
31. Oman TJ, Lupoli TJ, Wang T-SA, Kahne D, Walker S, Van der Donk WA. 2011. Haloduracin αbinds the peptidoglycan precursor lipid II with 2:1 stoichiometry. J. Am. Chem. Soc. 133:17544-47
32. Br̈ otz H, Josten M, Wiedemann I, Schneider U, G̈ otz F, et al. 1998. Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. Mol. Microbiol. 30:317-27
33. Bierbaum G, Szekat C, Josten M, Heidrich C, Kempter C, et al. 1996. Engineering of a novel thioether bridge and role of modified residues in the lantibiotic Pep5. Appl. Environ. Microbiol. 62:385-92
34. Lubelski J, Overkamp W, Kluskens LD, Moll GN, Kuipers OP. 2008. Influence of shifting positions of Ser, Thr, andCys residues in prenisin on the efficiency ofmodification reactions and on the antimicrobial activities of the modified prepeptides. Appl. Environ. Microbiol. 74:4680-85
35. Suda S, Westerbeek A, O'Connor PM, Ross RP, Hill C, Cotter PD. 2010. Effect of bioengineering lacticin 3147 lanthionine bridges on specific activity and resistance to heat and proteases. Chem. Biol. 17:1151-60
36. Kluskens LD, Nelemans SA, Rink R, de Vries L, Meter-Arkema A, et al. 2009. Angiotensin-(1-7) with thioether bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(1-7) analog. J. Pharmacol. Exp. Ther. 328:849-54
37. Rink R, Arkema-Meter A, Baudoin I, Post E, Kuipers A, et al. 2010. To protect peptide pharmaceuticals against peptidases. J. Pharmacol. Toxicol. Methods 61:210-18
38. Willey JM, Gaskell AA. 2011. Morphogenetic signaling molecules of the streptomycetes. Chem. Rev. 111:174-87
39. Meindl K, Schmiederer T, Schneider K, Reicke A, Butz D, et al. 2010. Labyrinthopeptins: a new class of carbacyclic lantibiotics. Angew. Chem. Int. Ed. 49:1151-54
40. Goto Y, Ö kesli A, Van der DonkWA. 2011. Mechanistic studies of Ser/Thr dehydration catalyzed by a member of the LanL lanthionine synthetase family. Biochemistry 50:891-98
41. Fischbach MA, Clardy J. 2007. One pathway, many products. Nat. Chem. Biol. 3:353-55
42. Li B, Sher D, Kelly L, Shi Y, Huang K, et al. 2010. Catalytic promiscuity in the biosynthesis of cyclic peptide secondary metabolites in planktonic marine cyanobacteria. Proc. Natl. Acad. Sci. USA 107:10430-35
43. Marsh A, O'Sullivan O, Ross RP, Cotter P, Hill C. 2010. In silico analysis highlights the frequency and diversity of type 1 lantibiotic gene clusters in genome sequenced bacteria. BMC Genomics 11:679
44. Begley M, Cotter PD, Hill C, Ross RP. 2009. Identification of a novel two-peptide lantibiotic, lichenicidin, following rational genome mining for LanM proteins. Appl. Environ. Microbiol. 75:5451-60
45. Wirawan RE, Klesse NA, Jack RW, Tagg JR. 2006. Molecular and genetic characterization of a novel nisin variant produced by Streptococcus uberis. Appl. Environ. Microbiol. 72:1148-56
46. Wieland Brown LC, Acker MG, Clardy J, Walsh CT, Fischbach MA. 2009. Thirteen posttranslational modifications convert a 14-residue peptide into the antibiotic thiocillin. Proc. Natl. Acad. Sci. USA 106:2549-53
47. Kelly WL, Pan L, Li C. 2009. Thiostrepton biosynthesis: prototype for a new family of bacteriocins. J. Am. Chem. Soc. 131:4327-34
48. Liao R, Duan L, Lei C, Pan H, Ding Y, et al. 2009. Thiopeptide biosynthesis featuring ribosomally synthesized precursor peptides and conserved posttranslational modifications. Chem. Biol. 16:141-47
49. Morris RP, Leeds JA, NaegeliHU, Oberer L, Memmert K, et al. 2009. Ribosomally synthesized thiopeptide antibiotics targeting elongation factor Tu. J. Am. Chem. Soc. 131:5946-55
50. Onaka H, Nakaho M, Hayashi K, Igarashi Y, Furumai T. 2005. Cloning and characterization of the goadsporin biosynthetic gene cluster from Streptomyces sp. TP-A0584. Microbiology 151:3923-33
51. Medema MH, Blin K, Cimermancic P, de Jager V, Zakrzewski P, et al 2011. antiSMASH: rapid identification, annotation and analysis of secondary metabolite biosynthesis gene clusters in bacterial and fungal genome sequences. Nucleic Acids Res. 39:W339-46
52. de Jong A, Van Heel AJ, Kok J, Kuipers OP. 2010. BAGEL2: mining for bacteriocins in genomic data. Nucleic Acids Res. 38:W647-51
53. Hammami R, Zouhir A, Le Lay C, Ben Hamida J, Fliss I. 2010. BACTIBASE second release: a database and tool platform for bacteriocin characterization. BMC Microbiol. 10:22
54. Haft DH, Basu MK. 2011. Biological systems discovery in silico: radical S-adenosylmethionine protein families and their target peptides for posttranslational modification. J. Bacteriol. 193:2745-55
55. Veĺasquez JE, Zhang X, Van der Donk WA. 2011. Biosynthesis of the antimicrobial peptide epilancin 15X and its N-terminal lactate. Chem. Biol. 18:857-67
56. Li B, Yu JPJ, Brunzelle JS, Moll GN, Van der Donk WA, Nair SK. 2006. Structure and mechanism of the lantibiotic cyclase involved in nisin biosynthesis. Science 311:1464-67
57. Li B, Van der Donk WA. 2007. Identification of essential catalytic residues of the cyclase NisC involved in the biosynthesis of nisin. J. Biol. Chem. 282:21169-75
58. Helfrich M, Entian K-D, SteinT. 2007. Structure-function relationships of the lanthionine cyclase SpaC involved in biosynthesis of the Bacillus subtilis peptide antibiotic subtilin. Biochemistry 46:3224-33
59. Kuipers A, de Boef E, Rink R, Fekken S, Kluskens LD, et al. 2004. NisT, the transporter of the lantibiotic nisin, can transport fully modified, dehydrated, and unmodified prenisin and fusions of the leader peptide with non-lantibiotic peptides. J. Biol. Chem. 279:22176-82
60. Moll GN, Kuipers A, Rink R. 2010. Microbial engineering of dehydro-amino acids and lanthionines in non-lantibiotic peptides. Antonie Van Leeuwenhoek 97:319-33
61. Van den Berg Van Saparoea HB, Bakkes PJ, Moll GN, Driessen AJM. 2008. Distinct contributions of the nisin biosynthesis enzymes NisB and NisC and transporter NisT to prenisin production by Lactococcus lactis. Appl. Environ. Microbiol. 74:5541-48
62. Lubelski J, Khusainov R, Kuipers OP. 2009. Directionality and coordination of dehydration and ring formation during biosynthesis of the lantibiotic nisin. J. Biol. Chem. 284:25962-72
63. Kuipers A, Meijer-Wierenga J, Rink R, Kluskens LD, Moll GN. 2008. Mechanistic dissection of the enzyme complexes involved in biosynthesis of lacticin 3147 and nisin. Appl. Environ. Microbiol. 74:6591-97
64. Mavaro A, Abts A, Bakkes PJ, Moll GN, Driessen AJM, et al. 2011. Substrate recognition and specificity of NisB, the lantibiotic dehydratase involved in nisin biosynthesis. J. Biol. Chem. 286:30552-60
65. Khusainov R, Heils R, Lubelski J, Moll GN, Kuipers OP. 2011. Determining sites of interaction between prenisin and its modification enzymes NisB and NisC. Mol. Microbiol. 82:706-18
66. Castiglione F, Lazzarini A, Carrano L, Corti E, Ciciliato I, et al. 2008. Determining the structure and mode of action of microbisporicin, a potent lantibiotic active against multiresistant pathogens. Chem. Biol. 15:22-31
67. Jab́es D, Brunati C, Candiani G, Riva S, Romańo G, Donadio S. 2011. Efficacy of the new lantibiotic NAI-107 in experimental infections induced by multidrug-resistant gram-positive pathogens. Antimicrob. Agents Chemother. 55:1671-76
68. Foulston LC, BibbMJ. 2010. Microbisporicin gene cluster reveals unusual features of lantibiotic biosynthesis in actinomycetes. Proc. Natl. Acad. Sci. USA 107:13461-66
69. Foulston L, Bibb M. 2011. Feed-forward regulation of microbisporicin biosynthesis in Microbispora corallina. J. Bacteriol. 193:3064-71
70. Castiglione F, Cavaletti L, Losi D, Lazzarini A, Carrano L, et al. 2007. A novel lantibiotic acting on bacterial cell wall synthesis produced by the uncommon actinomycete Planomonospora sp. Biochemistry 46:5884-95
71. Maffioli SI, Potenza D, Vasile F, De MatteoM, Sosio M, et al. 2009. Structure revision of the lantibiotic 97518. J. Nat. Prod. 72:605-7
72. Vasile F, Potenza D, Marsiglia B, Maffioli S, Donadio S. 2011. Solution structure by nuclear magnetic resonance of the two lantibiotics 97518 and NAI-107. J. Pept. Sci. 18:129-34
73. Xie L, Miller LM, Chatterjee C, Averin O, KelleherNL, Van der Donk WA. 2004. Lacticin 481: In vitro reconstitution of lantibiotic synthetase activity. Science 303:679-81
74. Chatterjee C, Miller LM, Leung YL, Xie L, Yi M, et al. 2005. Lacticin 481 synthetase phosphorylates its substrate during lantibiotic production. J. Am. Chem. Soc. 127:15332-33
75. You YO, Van der Donk WA. 2007. Mechanistic investigations of the dehydration reaction of lacticin 481 synthetase using site-directed mutagenesis. Biochemistry 46:5991-6000
76. You YO, Levengood MR, Furgerson Ihnken LA, Knowlton AK, Van der Donk WA. 2009. Lacticin 481 synthetase as a general serine/threonine kinase. ACS Chem. Biol. 4:379-85
77. Paul M, Patton GC, Van der Donk WA. 2007. Mutants of the zinc ligands of lacticin 481 synthetase retain dehydration activity but have impaired cyclization activity. Biochemistry 46:6268-76
78. Lee MV, Furgerson Ihnken LA, You YO, McClerren AL, Van der Donk WA, Kelleher NL. 2009. Distributive and directional behavior of lantibiotic synthetases revealed by high-resolution tandem mass spectrometry. J. Am. Chem. Soc. 131:12258-64
79. Zhang X, NiW, Van der DonkWA. 2007. On the regioselectivity of thioether formation by lacticin 481 synthetase. Org. Lett. 9:3343-46
80. Asaduzzaman SM, Nagao J, Iida H, Zendo T, Nakayama J, Sonomoto K. 2009. Nukacin ISK-1, a bacteriostatic lantibiotic. Antimicrob. Agents Chemother. 53:3595-98
81. Nagao J, Aso Y, Sashihara T, Shioya K, Adachi A, et al. 2005. Localization and interaction of the biosynthetic proteins for the lantibiotic, nukacin ISK-1. Biosci. Biotechnol. Biochem. 69:1341-47
82. Shioya K, Harada Y, Nagao J, Nakayama J, Sonomoto K. 2010. Characterization ofmodification enzyme NukMand engineering of a novel thioether bridge in lantibiotic nukacin ISK-1. Appl.Microbiol. Biotechnol. 86:891-99
83. Furgerson Ihnken LA, Chatterjee C, Van der Donk WA. 2008. In vitro reconstitution and substrate specificity of a lantibiotic protease. Biochemistry 47:7352-63
84. Plat A, Kluskens LD, Kuipers A, Rink R, Moll GN. 2011. Requirements of the engineered leader peptide of nisin for inducing modification, export, and cleavage. Appl. Environ. Microbiol. 77:604-11
85. Nishie M, Sasaki M, Nagao J, Zendo T, Nakayama J, Sonomoto K. 2011. Lantibiotic transporter requires cooperative functioning of the peptidase domain and the ATP binding domain. J. Biol. Chem. 286:11163-69
86. Nishie M, Shioya K, Nagao J, Jikuya H, Sonomoto K. 2009. ATP-dependent leader peptide cleavage by NukT, a bifunctional ABC transporter, during lantibiotic biosynthesis. J. Biosci. Bioeng. 108:460-64
87. Nagao J, Morinaga Y, Islam MR, Asaduzzaman SM, Aso Y, et al. 2009. Mapping and identification of the region and secondary structure required for thematuration of the nukacin ISK-1 prepeptide. Peptides 30:1412-20
88. Kotake Y, Ishii S, Yano T, Katsuoka Y, Hayashi H. 2008. Substrate recognition mechanism of the peptidase domain of the quorum-sensing-signal- producing ABC transporter ComA from Streptococcus. Biochemistry 47:2531-38
89. Ishii S, Yano T, Ebihara A, Okamoto A, Manzoku M, HayashiH. 2010. Crystal structure of the peptidase domain of Streptococcus ComA, a bifunctional ATP-binding cassette transporter involved in the quorumsensing pathway. J. Biol. Chem. 285:10777-85
90. Lawton EM, Ross RP, Hill C, Cotter PD. 2007. Two-peptide lantibiotics: a medical perspective. Mini Rev. Med. Chem. 7:1236-47
91. McClerrenAL, Cooper LE, Quan C, Thomas PM, KelleherNL, Van der DonkWA.2006. Discovery and in vitro biosynthesis of haloduracin, a two-component lantibiotic. Proc. Natl. Acad. Sci. USA 103:17243-48
92. Lawton EM, Cotter PD, Hill C, Ross RP. 2007. Identification of a novel two-peptide lantibiotic, haloduracin, produced by the alkaliphile Bacillus halodurans C-125. FEMS Microbiol. Lett. 267:64-71
93. Cooper LE, McClerren AL, Chary A, Van der Donk WA. 2008. Structure-activity relationship studies of the two-component lantibiotic haloduracin. Chem. Biol. 15:1035-45
94. Dischinger J, Josten M, Szekat C, Sahl HG, Bierbaum G. 2009. Production of the novel two-peptide lantibiotic lichenicidin by Bacillus licheniformis DSM 13. PLoS ONE 4:e6788
95. Shenkarev ZO, Finkina EI, Nurmukhamedova EK, Balandin SV, Mineev KS, et al. 2010. Isolation, structure elucidation, and synergistic antibacterial activity of a novel two-component lantibiotic lichenicidin from Bacillus licheniformis VK21. Biochemistry 49:6462-72
96. Caetano T, Krawczyk JM, M̈ osker E, S̈ ussmuth RD, Mendo S. 2011. Heterologous expression, biosynthesis, and mutagenesis of type II lantibiotics from Bacillus licheniformis in Escherichia coli. Chem. Biol. 18:90-100
97. Booth MC, Bogie CP, Sahl HG, Siezen RJ, Hatter KL, Gilmore MS. 1996. Structural analysis and proteolytic activation of Enterococcus faecalis cytolysin, a novel lantibiotic. Mol. Microbiol. 21:1175-84
98. Holo H, Jeknic Z, Daeschel M, Stevanovic S, Nes IF. 2001. PlantaricinWfrom Lactobacillus plantarum belongs to a new family of two-peptide lantibiotics. Microbiology 147:643-51
99. Haft DH, Basu MK, Mitchell DA. 2010. Expansion of ribosomally produced natural products: a nitrile hydratase-and Nif11-related precursor family. BMC Biol. 8:70
100. Wescombe PA, Upton M, Dierksen KP, Ragland NL, Sivabalan S, et al. 2006. Production of the lantibiotic salivaricin A and its variants by oral streptococci and use of a specific induction assay to detect their presence in human saliva. Appl. Environ. Microbiol. 72:1459-66
101. Hyink O, Wescombe PA, UptonM, Ragland N, Burton JP, Tagg JR. 2007. Salivaricin A2 and the novel lantibiotic salivaricin B are encoded at adjacent loci on a 190-kilobase transmissible megaplasmid in the oral probiotic strain Streptococcus salivarius K12. Appl. Environ. Microbiol. 73:1107-13
102. Wescombe PA, Upton M, Renault P, Wirawan RE, Power D, et al. 2011. Salivaricin 9, a new lantibiotic produced by Streptococcus salivarius. Microbiology 157:1290-99
103. Lin Y, Teng K, Huan L, Zhong J. 2011. Dissection of the bridging pattern of bovicin HJ50, a lantibiotic containing a characteristic disulfide bridge. Microbiol. Res. 166:146-54
104. Kabuki T, Uenishi H, Seto Y, Yoshioka T, Nakajima H. 2009. A unique lantibiotic, thermophilin 1277, containing a disulfide bridge and two thioether bridges. J. Appl. Microbiol. 106:853-62
105. Kodani S, Hudson ME, Durrant MC, Buttner MJ, Nodwell JR, Willey JM. 2004. The SapB morphogen is a lantibiotic-like peptide derived from the product of the developmental gene ramS in Streptomyces coelicolor. Proc. Natl. Acad. Sci. USA 101:11448-53
106. M̈ uller WM, Schmiederer T, Ensle P, S̈ ussmuth RD. 2010. In vitro biosynthesis of the prepeptide of type-III lantibiotic labyrinthopeptin A2 including formation of a C-C bond as a post-translational modification. Angew. Chem. Int. Ed. 49:2436-40
107. Pesic A, Henkel M, S̈ ussmuth RD. 2011. Identification of the amino acid labionin and its desulfurised derivative in the type-III lantibiotic LabA2 by means of GC/MS. Chem. Commun. 47:7401-3
108. Patton GC, Paul M, Cooper LE, Chatterjee C, Van der Donk WA. 2008. The importance of the leader sequence for directing lanthionine formation in lacticin 481. Biochemistry 47:7342-51
109. Chen P, Qi FX, Novak J, Krull RE, Caufield PW. 2001. Effect of amino acid substitutions in conserved residues in the leader peptide on biosynthesis of the lantibiotic mutacin II. FEMS Microbiol. Lett. 195:139-44
110. Neis S, Bierbaum G, Josten M, Pag U, Kempter C, et al. 1997. Effect of leader peptide mutations on biosynthesis of the lantibiotic Pep5. FEMS Microbiol. Lett. 149:249-55
111. M̈ uller WM, Ensle P, Krawczyk B, S̈ ussmuth RD. 2011. Leader peptide-directed processing of labyrinthopeptin A2 precursor peptide by the modifying enzyme LabKC. Biochemistry 50:8362-73
112. Chatterjee C, Patton GC, Cooper L, Paul M, Van der Donk WA. 2006. Engineering dehydro amino acids and thioethers into peptides using lacticin 481 synthetase. Chem. Biol. 13:1109-17
113. Sinha Roy R, Belshaw PJ, Walsh CT. 1998. Mutational analysis of posttranslational heterocycle biosynthesis in the gyrase inhibitor microcin B17: distance dependence from propeptide and tolerance for substitution in a GSCG cyclizable sequence. Biochemistry 37:4125-36
114. Levengood MR, Patton GC, Van der Donk WA. 2007. The leader peptide is not required for posttranslational modification by lacticin 481 synthetase. J. Am. Chem. Soc. 129:10314-15
115. Sit CS, Yoganathan S, Vederas JC. 2011. Biosynthesis of aminovinyl-cysteine-containing peptides and its application in the production of potential drug candidates. Acc. Chem. Res. 44:261-68
116. KupkeT, G̈ otz F. 1997. In vivo reaction of affinity-tag-labelled epidermin precursor peptide with flavoenzyme EpiD. FEMS Microbiol. Lett. 153:25-32
117. Ö kesli A, Cooper LE, Fogle EJ, Van der DonkWA. 2011. Nine post-translational modifications during the biosynthesis of cinnamycin. J. Am. Chem. Soc. 133:13753-60
118. Kupke T, Kempter C, Jung G, G̈ otz F. 1995. Oxidative decarboxylation of peptides catalyzed by flavoprotein EpiD. Determination of substrate specificity using peptide libraries and neutral loss mass spectrometry. J. Biol. Chem. 270:11282-89
119. He Z, Yuan C, Zhang L, Yousef AE. 2008. N-terminal acetylation in paenibacillin, a novel lantibiotic. FEBS Lett. 582:2787-92
120. He Z, Kisla D, Zhang L, Yuan C, Green-Church KB, Yousef AE. 2007. Isolation and identification of a Paenibacillus polymyxa strain that coproduces a novel lantibiotic and polymyxin. Appl. Environ. Microbiol. 73:168-78
121. Boakes S, Cort́es J, Appleyard AN, Rudd BAM, Dawson MJ. 2009. Organization of the genes encoding the biosynthesis of actagardine and engineering of a variant generation system. Mol. Microbiol. 72:1126-36
122. Boakes S, Appleyard AN, Cort́es J, Dawson MJ. 2010. Organization of the biosynthetic genes encoding deoxyactagardine B (DAB), a new lantibiotic produced by Actinoplanes liguriae NCIMB41362. J. Antibiot. 63:351-58
123. Liu G, Zhong J, Ni J, Chen M, Xiao H, Huan L. 2009. Characteristics of the bovicin HJ50 gene cluster in Streptococcus bovis HJ50. Microbiology 155:584-93
124. Xiao H, Chen X, Chen M, Tang S, Zhao X, Huan L. 2004. Bovicin HJ50, a novel lantibiotic produced by Streptococcus bovis HJ50. Microbiology 150:103-8
125. Oman TJ, Boettcher JM, Wang H, Okalibe XN, Van der Donk WA. 2011. Sublancin is not a lantibiotic but an S-linked glycopeptide. Nat. Chem. Biol. 7:78-80
126. Stepper J, Shastri S, Loo TS, Preston JC, Novak P, et al. 2011. Cysteine S-glycosylation, a new posttranslational modification found in glycopeptide bacteriocins. FEBS Lett. 585:645-50
127. Claesen J, Bibb M. 2010. Genome mining and genetic analysis of cypemycin biosynthesis reveal an unusual class of posttranslationally modified peptides. Proc. Natl. Acad. Sci. USA 107:16297-302
128. Claesen J, BibbMJ. 2011. Grisemycin, a new member of the linaridin family of ribosomally synthesized peptides produced by Streptomyces griseus IFO 13350: biosynthesis and regulation. J. Bacteriol. 193:2510-16
129. Field D, Hill C, Cotter PD, Ross RP. 2010. The dawning of a 'Golden era' in lantibiotic bioengineering. Mol. Microbiol. 78:1077-87
130. Ross AC, Vederas JC. 2011. Fundamental functionality: recent developments in understanding the structure-activity relationships of lantibiotic peptides. J. Antibiot. 64:27-34
131. Nagao J, Nishie M, Sonomoto K. 2011. Methodologies and strategies for the bioengineering of lantibiotics. Curr. Pharm. Biotechnol. 12:1221-30
132. Cort́es J, Appleyard AN, Dawson MJ, David AH. 2009. Whole-cell generation of lantibiotic variants. Methods Enzymol. 458:559-74
133. Field D, Connor PMO, Cotter PD, Hill C, Ross RP. 2008. The generation of nisin variants with enhanced activity against specific gram-positive pathogens. Mol. Microbiol. 69:218-30
134. Rink R, Wierenga J, Kuipers A, Kluskens LD, Driessen AJM, et al. 2007. Dissection and modulation of the four distinct activities of nisin by mutagenesis of rings A and B and by C-terminal truncation. Appl. Environ. Microbiol. 73:5809-16
135. Shi Y, Yang X, Garg N, Van der Donk WA. 2011. Production of lantipeptides in Escherichia coli. J. Am. Chem. Soc. 133:2338-41
136. Valsesia G, Medaglia G, Held M, MinasW, Panke S. 2007. Circumventing the effect of product toxicity: development of a novel two-stage production process for the lantibiotic gallidermin. Appl. Environ. Microbiol. 73:1635-45
137. Rink R, Wierenga J, Kuipers A, Kluskens LD, Driessen AJM, et al. 2007. Production of dehydroamino acid-containing peptides by Lactococcus lactis. Appl. Environ. Microbiol. 73:1792-96
138. Rink R, Kuipers A, de Boef E, Leenhouts KJ, Driessen AJM, et al. 2005. Lantibiotic structures as guidelines for the design of peptides that can be modified by lantibiotic enzymes. Biochemistry 44:8873-82
139. Kluskens LD, Kuipers A, Rink R, de Boef E, Fekken S, et al. 2005. Post-translational modification of therapeutic peptides by NisB, the dehydratase of the lantibiotic nisin. Biochemistry 44:12827-34
140. Rink R, Kluskens LD, Kuipers A, Driessen AJM, Kuipers OP, Moll GN. 2007. NisC, the cyclase of the lantibiotic nisin, can catalyze cyclization of designed nonlantibiotic peptides. Biochemistry 46:13179-89
141. Deegan LH, Suda S, Lawton EM, Draper LA, Hugenholtz F, et al. 2010. Manipulation of charged residues within the two-peptide lantibiotic lacticin 3147. Microb. Biotechnol. 3:222-34
142. Cotter PD, Deegan LH, Lawton EM, Draper LA, O'Connor PM, et al. 2006. Complete alanine scanning of the two-component lantibiotic lacticin 3147: generating a blueprint for rational drug design. Mol. Microbiol. 62:735-47
143. Islam MR, Shioya K, Nagao J, Nishie M, Jikuya H, et al. 2009. Evaluation of essential and variable residues of nukacin ISK-1 by NNK scanning. Mol. Microbiol. 72:1438-47
144. Appleyard AN, Choi S, Read DM, Lightfoot A, Boakes S, et al. 2009. Dissecting structural and functional diversity of the lantibiotic mersacidin. Chem. Biol. 16:490-98
145. Herzner AM, Dischinger J, Szekat C, Josten M, Schmitz S, et al. 2011. Expression of the lantibiotic mersacidin in Bacillus amyloliquefaciens FZB42. PLoS ONE 6:e22389
146. Nagao J, Harada Y, Shioya K, Aso Y, Zendo T, et al. 2005. Lanthionine introduction into nukacin ISK-1 prepeptide by co-expression with modification enzyme NukM in Escherichia coli. Biochem. Biophys. Res. Commun. 336:507-13
147. Nagao J, Shioya K, Harada Y, Okuda K, Zendo T, et al. 2011. Engineering unusual amino acids into peptides using lantibiotic synthetase. Methods Mol. Biol. 705:225-36
148. Caetano T, Krawczyk JM, Mosker E, Sussmuth RD, Mendo S. 2011. Lichenicidin biosynthesis in Escherichia coli: licFGEHI immunity genes are not essential for lantibiotic production or self-protection. Appl. Environ. Microbiol. 77:5023-26
149. Levengood MR, Knerr PJ, Oman TJ, Van der Donk WA. 2009. In vitro mutasynthesis of lantibiotic analogues containing nonproteinogenic amino acids. J. Am. Chem. Soc. 131:12024-25
150. Levengood MR, Kerwood CC, Chatterjee C, Van der Donk WA. 2009. Investigation of the substrate specificity of lacticin 481 synthetase by using nonproteinogenic amino acids. ChemBioChem 10:911-19
151. Levengood MR, Van der DonkWA. 2008. Use of lantibiotic synthetases for the preparation of bioactive constrained peptides. Bioorg. Med. Chem. Lett. 18:3025-28
152. Zhang X, Van derDonkWA. 2007. On the substrate specificity of dehydration by lacticin 481 synthetase. J. Am. Chem. Soc. 129:2212-13
153. Bindman N, Merkx R, Koehler R, Herrman N, Van der Donk WA. 2010. Photochemical cleavage of leader peptides. Chem. Commun. 46:8935-37
154. Cheng F, Takala TM, Saris PEJ. 2007. Nisin biosynthesis in vitro. J. Mol. Microbiol. Biotechnol. 13:248-54
155. Goto Y, Iwasaki K, Torikai K, Murakami H, Suga H. 2009. Ribosomal synthesis of dehydrobutyrineand methyllanthionine-containing peptides. Chem. Commun. 45:3419-21
156. Seebeck FP, Ricardo A, Szostak JW. 2011. Artificial lantipeptides from in vitro translations. Chem. Commun. 47:6141-43
157. Tabor AB. 2011. The challenge of the lantibiotics: synthetic approaches to thioether-bridged peptides. Org. Biomol. Chem. 9:7606-28
158. Fukase K, KitazawaM, Sano A, Shimbo K, Horimoto S, et al. 1992. Synthetic study on peptide antibiotic nisin. V. Total synthesis of nisin. Bull. Chem. Soc. Jpn. 65:2227-40
159. Ross AC, Liu H, PattabiramanVR, Vederas JC. 2010. Synthesis of the lantibiotic lactocin S using peptide cyclizations on solid phase. J. Am. Chem. Soc. 132:462-63
160. Pattabiraman VR, McKinnie SMK, Vederas JC. 2008. Solid-supported synthesis and biological evaluation of the lantibiotic peptide bis(desmethyl) lacticin 3147 A2. Angew. Chem. Int. Ed. 47:9472-75
161. Liu H, Pattabiraman VR, Vederas JC. 2009. Synthesis and biological activity of oxa-lacticin A2, a lantibiotic analogue with sulfur replaced by oxygen. Org. Lett. 11:5574-77
162. Pattabiraman VR, Stymiest JL, Derksen DJ, Martin NI, Vederas JC. 2007. Multiple on-resin olefin metathesis to form ring-expanded analogues of the lantibiotic peptide, lacticin 3147 A2. Org. Lett. 9:699-702
163. Knerr PJ, Tzekou A, Ricklin D, Qu H, Chen H, et al. 2011. Synthesis and activity of thioether-containing analogues of the complement inhibitor compstatin. ACS Chem. Biol. 6:753-60
164. LiuW, Chan ASH, Liu H, Cochrane SA, Vederas JC. 2011. Solid supported chemical syntheses of both components of the lantibiotic lacticin 3147. J. Am. Chem. Soc. 133:14216-19